Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2003 | 12-2002 | 09-2002 | 06-2002 | 03-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,950 | -15,690 | -12,170 | -8,200 | -4,990 |
| Depreciation Amortization | 60 | 770 | 560 | 400 | 190 |
| Other Working Capital | -1,670 | 1,420 | 1,290 | 410 | 80 |
| Other Operating Activity | 10 | 5,250 | 3,390 | 2,480 | 2,220 |
| Operating Cash Flow | $-3,550 | $-8,250 | $-6,930 | $-4,910 | $-2,500 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -40 | -3 | 70 | 70 |
| Other Investing Activity | 0 | -1,150 | -997 | -490 | 0 |
| Investing Cash Flow | $0 | $-1,190 | $-1,000 | $-420 | $70 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | -30 | 12,860 | 12,870 | 12,930 | 7,960 |
| Financing Cash Flow | $-30 | $12,860 | $12,870 | $12,930 | $7,960 |
| Beginning Cash Position | 14,720 | 11,300 | 11,300 | 11,300 | 11,300 |
| End Cash Position | 11,130 | 14,720 | 16,240 | 18,900 | 16,840 |
| Net Cash Flow | $-3,590 | $3,410 | $4,930 | $7,590 | $5,530 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,550 | -8,250 | -6,930 | -4,910 | -2,500 |
| Free Cash Flow | -3,550 | -8,250 | -6,930 | -4,910 | -2,500 |